$IGXT financials after close OTC $0.60 Record
Post# of 63703
Posted On: 03/22/2016 5:32:43 PM
$IGXT financials after close
OTC $0.60
Record 2015 Financial Results
an increase of 82% over the same period last year
Website
Shares Outstanding: 63.62M
Float: 53.15M
% Held by Insiders: N/A
Headlines
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0010/2006 for cancer pain; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013, INT0039/2013, and INT0040/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. It also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada .
OTC $0.60
Record 2015 Financial Results
an increase of 82% over the same period last year
Website
Shares Outstanding: 63.62M
Float: 53.15M
% Held by Insiders: N/A
Headlines
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0010/2006 for cancer pain; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013, INT0039/2013, and INT0040/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. It also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada .
(0)
(0)Scroll down for more posts ▼